Jane L Liesveld

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. ncbi Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines
    Jane L Liesveld
    Department of Medicine, Hematology Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA jane
    Cancer Invest 29:439-50. 2011
  2. ncbi Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells
    Jane L Liesveld
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA
    Leuk Res 31:1553-63. 2007
  3. ncbi Acute myelogenous leukemia--microenvironment interactions: role of endothelial cells and proteasome inhibition
    Jane L Liesveld
    University of Rochester, University of Rochester Medical Center, Department of Medicine and the James P. Wilmot Cancer Center, Rochester, NY 14642, USA
    Hematology 10:483-94. 2005
  4. ncbi A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection
    Gordon L Phillips
    Hematology Oncology, University of Rochester Medical Center, James P Wilmot Cancer Center, Strong Memorial Hospital, Rochester, New York 14642, USA
    Biol Blood Marrow Transplant 17:1033-42. 2011
  5. ncbi The hematopoietic stem cell in myelodysplasia
    Jane L Liesveld
    Leukemia Blood and Marrow Transplant Program, Rochester, NY, USA
    Stem Cells 22:590-9. 2004
  6. ncbi Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)
    Monica L Guzman
    James P Wilmot Cancer Center, University of Rochester, NY 14642, USA
    Blood 110:4436-44. 2007
  7. ncbi Optimal cytokine stimulation for the enhanced generation of leukemic dendritic cells in short-term culture
    Nicki Panoskaltsis
    The University of Rochester Medical Center, Department of Internal Medicine, Hematology Oncology Unit, Box 610, Rochester, NY 14642, USA
    Leuk Res 26:191-201. 2002
  8. ncbi Flavonoid effects on normal and leukemic cells
    Jane L Liesveld
    Department of Medicine, James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA
    Leuk Res 27:517-27. 2003
  9. ncbi Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin
    Martin S Zand
    Division of Nephrology, University of Rochester Medical Center, 601 Elmwood Ave, Box 675, Rochester, NY 14642, USA
    Blood 107:2895-903. 2006
  10. ncbi Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients
    Jane L Liesveld
    Blood and Marrow Transplant Program, James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA
    Biol Blood Marrow Transplant 8:662-5. 2002

Collaborators

Detail Information

Publications12

  1. ncbi Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines
    Jane L Liesveld
    Department of Medicine, Hematology Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA jane
    Cancer Invest 29:439-50. 2011
    ..Combinations with arsenic trioxide, sorafenib, and cytarabine demonstrated synergistic in vitro effects in AML cell lines...
  2. ncbi Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells
    Jane L Liesveld
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA
    Leuk Res 31:1553-63. 2007
    ..This work confirms that AML is influenced by the SDF-1alpha/CXCR4 axis and demonstrates that disruption of this axis by the bicyclam AMD3100 can influence AML microenvironmental interactions...
  3. ncbi Acute myelogenous leukemia--microenvironment interactions: role of endothelial cells and proteasome inhibition
    Jane L Liesveld
    University of Rochester, University of Rochester Medical Center, Department of Medicine and the James P. Wilmot Cancer Center, Rochester, NY 14642, USA
    Hematology 10:483-94. 2005
    ..These studies demonstrate that AML is subject to influence of endothelial cells and of agents such as bortezomib which have potential impact on AML interaction with the microenvironmental niche...
  4. ncbi A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection
    Gordon L Phillips
    Hematology Oncology, University of Rochester Medical Center, James P Wilmot Cancer Center, Strong Memorial Hospital, Rochester, New York 14642, USA
    Biol Blood Marrow Transplant 17:1033-42. 2011
    ..A Phase II trial is planned...
  5. ncbi The hematopoietic stem cell in myelodysplasia
    Jane L Liesveld
    Leukemia Blood and Marrow Transplant Program, Rochester, NY, USA
    Stem Cells 22:590-9. 2004
    ....
  6. ncbi Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)
    Monica L Guzman
    James P Wilmot Cancer Center, University of Rochester, NY 14642, USA
    Blood 110:4436-44. 2007
    ..We conclude that TDZD-8 uses a unique and previously unknown mechanism to rapidly target leukemia cells, including malignant stem and progenitor populations...
  7. ncbi Optimal cytokine stimulation for the enhanced generation of leukemic dendritic cells in short-term culture
    Nicki Panoskaltsis
    The University of Rochester Medical Center, Department of Internal Medicine, Hematology Oncology Unit, Box 610, Rochester, NY 14642, USA
    Leuk Res 26:191-201. 2002
    ..Optimal growth and DC characteristics were obtained with GM-CSF, FL, and SCF in 3-5 day cultures, suggesting a practical strategy for the immunotherapy of leukemia...
  8. ncbi Flavonoid effects on normal and leukemic cells
    Jane L Liesveld
    Department of Medicine, James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA
    Leuk Res 27:517-27. 2003
    ..These flavonoid compounds might find use in various therapeutic settings in AML...
  9. ncbi Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin
    Martin S Zand
    Division of Nephrology, University of Rochester Medical Center, 601 Elmwood Ave, Box 675, Rochester, NY 14642, USA
    Blood 107:2895-903. 2006
    ..We conclude that rATG is an effective agent for in vitro induction of apoptosis in multiple myeloma, and that exploratory clinical trials may be warranted...
  10. ncbi Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients
    Jane L Liesveld
    Blood and Marrow Transplant Program, James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA
    Biol Blood Marrow Transplant 8:662-5. 2002
    ..This study demonstrates the feasibility and significant cost savings of using oral VAL for HSV prophylaxis...
  11. ncbi Isodicentric Philadelphia chromosomes in imatinib mesylate (Gleevec)-resistant patients
    Christine M Szych
    Department of Pathology, University of Rochester, Strong Memorial Hospital, 601 Elmwood Avenue, P O Box 704, Rochester, NY 14642, USA
    Cancer Genet Cytogenet 174:132-7. 2007
    ..The impact of the isodicentric Philadelphia chromosomes on genomic instability, heterogeneity, and amplification of the Philadelphia chromosomes in IM-resistant patients is discussed...
  12. ncbi Rapid method for detection of mutations in the nucleophosmin gene in acute myeloid leukemia
    Todd S Laughlin
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
    J Mol Diagn 10:338-45. 2008
    ..Using a 100 nmol/L concentration of the LNA clamp, NPM1 mutations were detectable in a 10-fold excess of wild-type DNA. This assay may be valuable for screening disease specimens...